文献速递湿疹皮炎与荨麻疹

中重度特应性皮炎由度普利尤单抗换用乌帕替尼与持续乌帕替尼治疗的疗效与安全性

Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up).
PubMed 文献 · J Am Acad Dermatol · 2023-05-23

Heads Up 3b 期随机对照试验的 52 周开放标签扩展研究,预设中期 16 周分析纳入完成 24 周度普利尤单抗或乌帕替尼 30 mg 治疗的患者,全部改用乌帕替尼 30 mg。持续乌帕替尼者维持高水平皮损与瘙痒应答,换药者在 4 周内进一步改善,至 40 周未观察到新安全性风险。

要点

  • 持续乌帕替尼 30 mg 至 40 周可维持高水平皮损与瘙痒应答。
  • 度普利尤单抗治疗 24 周后换用乌帕替尼,4 周内临床应答进一步提高。
  • 多数度普利尤单抗应答不足者换用乌帕替尼后达到足够临床应答。

核心结论

  • 持续乌帕替尼治疗至 40 周可维持临床应答,无论既往度普利尤单抗应答如何,换用乌帕替尼后结局均改善。
  • 乌帕替尼至 40 周的安全性特征与既往 3 期特应性皮炎研究一致,未观察到新安全性风险。

研究设计与样本

  • Heads Up 为 3b 期随机对照试验,比较口服乌帕替尼 30 mg 与注射度普利尤单抗 300 mg。
  • 完成 Heads Up 后进入 52 周开放标签扩展研究(NCT04195698),开放标签期全部患者接受乌帕替尼 30 mg。
  • 本报告为预设的开放标签扩展 16 周中期分析,持续乌帕替尼组 n=239,换药组 n=245。

主要发现

  • 持续乌帕替尼组(n=239)维持高水平皮损与瘙痒应答。
  • 换药组(n=245)在开始乌帕替尼后 4 周内临床应答出现进一步增量改善。
  • 多数度普利尤单抗未达到足够临床应答的患者,换用乌帕替尼后达到足够临床应答。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 开放标签研究设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Characterization of upadacitinib use and switching from dupilumab to upadacitinib among patients with moderate-to-severe atopic dermatitis (AD) is needed. OBJECTIVE: To evaluate the long-term safety and efficacy of continuous upadacitinib 30 mg and switching to upadacitinib after 24 weeks of dupilumab. METHODS: Adults who completed the phase 3b clinical trial of oral upadacitinib 30 mg vs injectable dupilumab 300 mg (Heads Up) and entered a 52-week open-label extension (OLE) (NCT04195698) were included. All patients received 30-mg upadacitinib during the open-label period. We report results of a prespecified interim OLE 16-week analysis. RESULTS: Patients (n = 239) continuing upadacitinib maintained high levels of skin and itch response. Patients (n = 245) switching from dupilumab experienced additional incremental improvements in clinical responses within 4 weeks of starting upadacitinib. Most patients who did not achieve adequate clinical responses with dupilumab did so with upadacitinib. The safety profile of upadacitinib up to 40 weeks (week 16 of OLE) was consistent with previous phase 3 AD studies, with no new safety risks observed. LIMITATIONS: Open-label study design. CONCLUSIONS: Clinical responses are maintained with continuous upadacitinib through 40 weeks and patients regardless of prior dupilumab response experienced improved outcomes when switched to upadacitinib. No new safety risks were observed.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Blauvelt A, Ladizinski B, Prajapati VH, et al. Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up). J Am Acad Dermatol. 2023. PMID: 37230366. doi:10.1016/j.jaad.2023.05.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。